Related references
Note: Only part of the references are listed.Population Pharmacokinetics and Safety of Dasatinib in Chinese Children with Core-Binding Factor Acute Myeloid Leukemia
Fan Yang et al.
CLINICAL PHARMACOKINETICS (2022)
Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics
Shiyu He et al.
FRONTIERS IN PHARMACOLOGY (2021)
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients
Philippe Rousselot et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group
Noriyoshi Iriyama et al.
INTERNAL MEDICINE (2018)
Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
Raquel C. Maia et al.
MOLECULES (2018)
Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy
Liang Gong et al.
PHARMACOGENETICS AND GENOMICS (2017)
Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg
Hidekazu Itamura et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Predictive performance of eleven pharmacokinetic models for propofol infusion in children for long-duration anaesthesia
M. Hara et al.
BRITISH JOURNAL OF ANAESTHESIA (2017)
Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients
Celeste Bloomfield et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib
Geraldine Dessilly et al.
SCIENTIFIC REPORTS (2016)
Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia
Masatomo Miura
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
Drug metabolism for the paediatrician
Saskia N. de Wildt et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2014)
Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
Huixin Yu et al.
CLINICAL PHARMACOKINETICS (2014)
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study
Xiaoning Wang et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2013)
Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation
Naoto Takahashi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR
Antonia H. Tolson et al.
ADVANCED DRUG DELIVERY REVIEWS (2010)
Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia
Dong-Wook Kim et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects With Chronic Myeloid Leukemia
Guowei Dai et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Share Paper
